News & views
Our collective understanding of mental health is increasing all the time, with advances in neuroscience, psychotherapy, psychopharmacology and digital platforms.
For media inquiries, contact us at media@compasspathways.com
September 06, 2023
COMPASS Pathways announces publication of first study evaluating potential of AI model to predict outcomes of COMP360 psilocybin treatment in treatment-resistant depression
August 16, 2023
COMPASS Pathways Announces Up to $285 Million Private Placement Financing Joined by Leading Healthcare Investors
August 03, 2023
COMPASS Pathways Announces Second Quarter 2023 Financial Results and Business Highlights
July 25, 2023
First clinical study results of psilocybin treatment in anorexia nervosa published in Nature Medicine
July 17, 2023
COMPASS Pathways announces publication of positive data from treatment-resistant depression phase 2 clinical trial of COMP360 psilocybin alongside antidepressants in Nature journal, Neuropsychopharmacology
July 13, 2023
Opinion paper calls for clarity on the definition of “psychedelic-assisted therapy” using psilocybin
July 06, 2023
American Medical Association Releases Language of First New Current Procedural Terminology Code for Psychedelic Therapies
July 05, 2023
COMPASS Pathways Secures Term Loan Facility for Up to $50 Million from Hercules Capital
June 06, 2023
COMPASS Pathways key patents upheld by the US Patent and Trademark Office
May 31, 2023
COMPASS Pathways’ Co-Founder Ekaterina Malievskaia to Step Down as Chief Innovation Officer
May 26, 2023
Data demonstrating long-term improvement in depression in cancer patients following single dose of COMP360 psilocybin therapy to be presented at ASCO 2023
May 11, 2023
COMPASS Pathways Announces First Quarter 2023 Financial Results and Business Highlights
May 02, 2023
American Medical Association to Issue First New Code for Psychedelic Therapies
February 28, 2023
COMPASS Pathways Announces Fourth Quarter and Year-End 2022 Financial Results and Business Highlights
December 08, 2022
COMP360 psilocybin therapy shows potential in open-label study in type II bipolar disorder presented at ACNP
November 03, 2022
COMPASS Pathways Announces Third Quarter 2022 Financial Results and Business Highlights
November 03, 2022
COMPASS Pathways announces publication of phase 2b study of COMP360 psilocybin therapy for treatment-resistant depression in The New England Journal of Medicine
October 27, 2022
COMPASS Pathways plc to announce third quarter 2022 financial results on 3 November 2022
October 12, 2022
COMPASS Pathways Announces Phase 3 Pivotal Program Design for COMP360 in Treatment Resistant Depression at Capital Markets Day
October 04, 2022
COMPASS Pathways to Hold Virtual Capital Market Day on 12 October 2022